OncLive SOSS

Authors

Maurice Perol, MD

Latest:

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer.

Latest:

Time Required to Address Scientific Questions Generates an Information Dilemma

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Maurie Markman, MD

Maurie Markman, MD, is president of Medicine & Science at City of Hope Atlanta, Chicago, and Phoenix

Latest:

Confronting the Giant in the Room: Cancer Management Needs Real Decision-Support Tools

Maurie Markman, MD, discusses the role of decision support tools in cancer management.

Maurie Markman, MD, CTCA

Latest:

Dr Markman on the Role of PARP Inhibitors in Ovarian Cancer

Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.

Max S. Topp, MD

Latest:

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Max S. Topp, MD, University Hospital of Wuerzburg

Max S. Wicha, MD

Latest:

Wicha Sees Potential for Significant Expansion of Anti-HER2 Therapy

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Max Topp, MD, University Hospital of Wuerzburg

Latest:

The New Medical Oncology/Palliative Medicine Fellowship Track

Medical oncology is a complex field, rich in basic science, mechanism of actions, and cutting-edge clinical investigation but also physical, emotional, social, and existential distress for the patient.

Maximilian Diehn, MD, PhD

Latest:

Dr. Diehn on Next Steps With Liquid Biopsies in Lung Cancer

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

Maximilian Hochmair, MD, Otto Wagner Spital

Maxine S. Jochelson, MD

Latest:

Dr. Jochelson on the Limitations of Mammography and Ultrasound in Screening for Breast Cancer

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

Maya E. Guglin, MD, PhD

Latest:

Preventing Chemotherapy-Induced Cardiomyopathy: Can We? Should We?

Anthracyclines widely used for a variety of malignancies cause cardiotoxic effects that manifest as cardiomyopathy. Maya E. Guglin, MD, PhD, discusses supportive therapy for these patients.

Mayer Fishman, MD, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Mazyar Shadman, MD, MPH

Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and an associate professor, in theClinical Research Division at Fred Hutchinson Cancer. He is also an associate professor in the Medical Oncology Division at University of Washington School of Medicine.

Latest:

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center

Latest:

A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

McKesson Specialty Health

Latest:

Saving Time, Money, and Trouble With an Inventory Management Upgrade

Changes in cancer care, regulations, and reimbursement create more pressure on practices than ever before to improve care, reduce costs, and remain viable in an atmosphere of mergers and acquisitions.

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

MD Anderson Cancer Center

Latest:

CPRIT Awards MD Anderson Over $29 million for Prevention Efforts, Cancer Research, and Faculty Recruitment

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

Latest:

20 Best Health 2.0 Tools for Physicians and Patients

The premise of Health 2.0 rests on one simple idea: whatever your healthcare question or concern may be, there is a potential community of likeminded individuals out there who are ready and willing to share.